Tao-Tao Liu
Overview
Explore the profile of Tao-Tao Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
111
Citations
1368
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Niu L, Liu Y, Wu Y, Huang T, Wu T, Xiao Y, et al.
Eur J Drug Metab Pharmacokinet
. 2025 Feb;
50(2):161-173.
PMID: 39891881
Background And Objectives: As an immunosuppressant, mycophenolate mofetil (MMF) is used to prevent graft versus host disease (GVHD) in patients after hematopoietic stem cell transplantation (HCT). This study aimed to...
2.
He Y, Wei Y, Huang G, Liu G, Lin Z, Liu T, et al.
Pharmacotherapy
. 2024 Oct;
44(11):861-869.
PMID: 39441027
Background: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have been shown to improve cardiovascular outcomes by reducing low-density lipoprotein cholesterol (LDL-C). However, sex differences in the efficacy of evolocumab remain...
3.
Zhang G, Song K, Wang X, He Z, Du J, Sun J, et al.
Colloids Surf B Biointerfaces
. 2024 Oct;
245:114279.
PMID: 39368423
Sorafenib (SOR), a multi-kinase inhibitor for advanced hepatocellular carcinoma (HCC), has limited clinical application due to severe side effects and drug resistance. To overcome these challenges, we developed a bismuth-based...
4.
Huang C, Wang S, Liu T, Wu M, Cai K, Xie Z, et al.
Recent Pat Anticancer Drug Discov
. 2024 Jul;
PMID: 38994622
Background: The emergence of drug resistance to oxaliplatin (OXA) is one of the critical obstacles in the therapy of advanced Hepatocellular Carcinoma (HCC). As an ethyl derivative of the natural...
5.
Meng D, Liu T, Wu M, He J, Du S, Huang Y
Dalton Trans
. 2024 Jul;
53(30):12486-12493.
PMID: 38952336
The development of heteroatom dual-doped porous carbon frameworks with uniform doping is highly desirable for achieving highly efficient oxygen reduction reaction (ORR) activity, due to their tunable chemical and electronic...
6.
Liu Z, Lin X, Guo H, Shi X, Zhang D, Sun J, et al.
Int J Biol Sci
. 2024 May;
20(7):2763-2778.
PMID: 38725845
Dysregulation of the aldehyde dehydrogenase (ALDH) family has been implicated in various pathological conditions, including cancer. However, a systematic evaluation of ALDH alterations and their therapeutic relevance in hepatocellular carcinoma...
7.
Lu J, Liu T
Am J Cardiovasc Drugs
. 2024 Feb;
24(2):303-311.
PMID: 38300453
Background: Digoxin is primarily metabolized by the kidney, and its toxicity is strongly associated with high concentrations, particularly in elderly patients. The purpose of this study was to evaluate the...
8.
Wang F, Xu W, Zhang W, Xu R, Sun J, Zhang G, et al.
Hepatol Int
. 2023 Nov;
18(2):636-650.
PMID: 37982952
Background: Aberrant iron metabolism is commonly observed in multiple tumor types, including hepatocellular carcinoma (HCC). However, as the key regulator of iron metabolism involved in iron absorption, the role of...
9.
Shi X, Wang J, Rao S, Liu T, Wu H
Front Pharmacol
. 2023 Sep;
14:1246657.
PMID: 37663264
A number of patients with Crohn's disease (CD) suffer from loss of response to infliximab (IFX) therapy. Splenic volume is reported to be enlarged in patients with CD compared to...
10.
Liu H, Yao C, Wang X, Zhang N, Chen Y, Pan D, et al.
World J Gastroenterol
. 2023 Feb;
29(4):706-730.
PMID: 36742169
Background: The diagnostic and economic value of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9) and CA72-4 for gastrointestinal malignant tumors lacked evaluation in a larger scale. Aim: To reassess the...